
1. malar j. 2016 feb 18;15:96. doi: 10.1186/s12936-016-1141-9.

plasmodium vivax mdr1 genotypes isolates successfully cured patients
living endemic non-endemic brazilian areas.

gomes lr(1)(2), almeida-de-oliveira nk(3)(4), de lavigne ar(5)(6), de lima
sr(7)(8), de pina-costa a(9)(10), brasil p(11)(12), daniel-ribeiro ct(13)(14),
ménard d(15), ferreira-da-cruz mde f(16)(17).

author information: 
(1)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo 
cruz (fiocruz), rio de janeiro, brazil. larissagomesr@gmail.com.
(2)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. larissagomesr@gmail.com.
(3)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo 
cruz (fiocruz), rio de janeiro, brazil. nataliaketrin@gmail.com.
(4)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. nataliaketrin@gmail.com.
(5)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo 
cruz (fiocruz), rio de janeiro, brazil. alinelavigne@uol.com.br.
(6)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. alinelavigne@uol.com.br.
(7)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo 
cruz (fiocruz), rio de janeiro, brazil. suelen.lima@ioc.fiocruz.br.
(8)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. suelen.lima@ioc.fiocruz.br.
(9)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. anielle.pina@hotmail.com.
(10)laboratório de doenças febris agudas - instituto nacional de infectologia
evandro chagas (ini-ipec) (fiocruz), rio de janeiro, brazil.
anielle.pina@hotmail.com.
(11)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. patricia.brasil@ini.fiocruz.br.
(12)laboratório de doenças febris agudas - instituto nacional de infectologia
evandro chagas (ini-ipec) (fiocruz), rio de janeiro, brazil.
patricia.brasil@ini.fiocruz.br.
(13)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo
cruz (fiocruz), rio de janeiro, brazil. ctdr@uol.com.br.
(14)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. ctdr@uol.com.br.
(15)malaria molecular epidemiology unit, institut pasteur cambodia, phnom
penh, cambodia. dmenard@pasteur-kh.org.
(16)laboratório de pesquisa em malária - instituto oswaldo cruz, fundação oswaldo
cruz (fiocruz), rio de janeiro, brazil. mffcruz28@gmail.com.
(17)centro de pesquisa, diagnóstico e treinamento em malária (cpd-mal) fiocruz,
rio de janeiro, brazil. mffcruz28@gmail.com.

background: plasmodium vivax widely distributed species causing the
highest number malaria cases world. brazil, p. vivax responsible 
for approximately 84 % reported cases. absence vaccine, control
strategies based management cases rapid diagnosis and
adequate treatment, addition vector control measures. approaches used
to investigate p. vivax resistance chloroquine (cq) exclusively vivo
studies difficulty keeping parasites continuous vitro
culture. view limitations related follow-up patients to
assessing plasma dosage cq metabolites, alternative approach to
monitor chemo-resistance (qr) use molecular markers. single nucleotide
polymorphisms (snps) multidrug resistance gene pvmdr1 putative
determinants cq resistance (cqr), snps p. vivax isolates from
patients good response treatment explored. aim of
this study investigate mutations gene, supposedly associated 
qr, p. vivax isolates successfully cured patients, living brazilian
endemic non-endemic areas.
methods: blood samples collected 49 vivax malaria patients endemic
(amazon basin: 45) non-endemic (atlantic forest: four) brazilian regions 
analysed snps cqr-related p. vivax gene (pvmdr1), using pcr-based
methods.
results: among 49 isolates genetically characterized gene pvmdr1, 34 
(70 %) presented least one mutation. t958m mutant alleles most
frequent (73 %) followed y976f (15 %) f1076l (12 %). single mutation was
detected 24 (70.5 %) isolates double mutations ten (29.5 %). most
common single mutant genotype 958m/y976/f1076 (79 %), followed by
976f/f1076 (21 %) whereas 958m/y976/1076l (60 %) 976f/1076l (40 %) double
mutant genotypes detected. single mutant profile observed in
isolates amazon basin, although double mutants found amazon
and atlantic forest regions. interestingly, genotype 958m/y976/1076l was
present isolates atlantic forest rio de janeiro state.
conclusions: considering primaquine (pq) efficacy highly dependent on
concurrent administration blood schizontocidal agent pq could not
circumvent cqr, together fact pvmdr1 mutation expected
in successfully cured patients, findings seem indicate pvmdr1
gene reliable marker cqr. investigations needed define
a reliable molecular marker monitoring p. vivax cqr p. vivax populations.

doi: 10.1186/s12936-016-1141-9 
pmcid: pmc4758108
pmid: 26887935  [indexed medline]

